Fed. Circ. Nixes Pronova's Patent Win Against Teva, Par

Law360, New York (September 12, 2013, 5:52 PM EDT) -- Pronova BioPharma Norge AS rendered its patent for the triglyceride-lowering drug Lovaza invalid when it sent a doctor samples of the drug before seeking a patent, the Federal Circuit ruled Thursday in a victory for generics makers Teva Pharmaceuticals USA Inc. and Par Pharmaceutical Inc.

The appeals court reversed a lower court's ruling that Pronova's patent is valid and that Teva and Par's planned generic version of the drug infringed, clearing the way for the two companies to launch their products.

The case hinged on the...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.